Biochemistry and pharmacology of catechol-O-methyltransferase inhibitors
Erkki Nissinen1, Pekka T Männistö
1Orion Pharma, Research Center, Espoo, Finland.
Abstract:
Catechol-O-methyltransferase (COMT) is an important enzyme in the metabolism of catechol structured compounds such as catecholamines, catecholestrogens, and L-dopa. When combined with decarboxylase inhibitor L-dopa is the most efficacious treatment for Parkinson's disease. Bioavailability and efficacy of L-dopa treatment can be enhanced greatly by the use of COMT inhibitors. This has been the driving force for development of new selective and potent COMT inhibitors. The success in COMT inhibitor development has generated a tremendous scientific interest in the role of COMT in health and disease. COMT inhibitors have also helped to clarify the reaction mechanism of COMT, increased interest in its structural biology, and physicochemical properties in order to develop even better COMT inhibitors. New techniques, especially the transgenic mice, have revealed further new aspects about the role of COMT in periphery as well as in the brain.
Related Concept Videos
Drugs Affecting Neurotransmitter Synthesis
Adrenergic Agonists: Indirect-Acting Agents
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
Drugs Affecting Neurotransmitter Release or Uptake
Phase II Reactions: Methylation Reactions
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase


